伊贝沙坦与缬沙坦治疗轻中度高血压的比较

Comparison Between Irbsartan and Valsartan on Treatment of Mild to Moderate Essential Hypertension

目的：比较国产伊贝沙坦与进口缬沙坦降压疗效及安全性。方法：轻中度高血压病人２１６例，采用随机双盲双模拟研究方法，伊贝沙坦组 １１０例，缬沙坦组１０６例。起始剂量分别为１５０ｍｇ·ｄ－１与８０ｍｇ·ｄ－１，２周后未达有效则分别增加至３００ｍｇ·ｄ－１或１６０ｍｇ·ｄ－１，疗程４周。开盲后伊贝沙坦组有效者继续开放服用１个月，共８周。另２１例服伊贝沙坦１５０ｍｇ·ｄ－１的患者做ＡＢＰＭ，进行Ｔ／Ｐ比值的分析。结果：随机双盲治疗４周开盲后统计，２组患者治疗２周、４周血压均明显下降，与治疗前相比有显著性差异（Ｐ＜０．００１），总有效率分别为７８．２％及７４．５％。２组有效率无显著性差异。伊贝沙坦开放组血压从４周～８周呈稳定下降，Ｔ／Ｐ值５３．５％。两药的不良反应分别为１７．１％及１３．９％。均较轻，可耐受。结论：两种血管紧张素Ⅱ受体拮抗药均是治疗轻中度高血压的有效而安全的药物。

OBJECTIVE: To evaluate the efficacy and safety of irbsartan and valsartan in treating essential hypertension. METHODS: 2 1 6 patients with mild to moderate essential hypertension were enrolled in and divided into 2 groups by randomized, double blind and double simulate, group A(irbsartan) 110 cases and group B (valsartan) 106 cases. Patients were treated with irbsartan 150-300mg.d-1 or valsartan 80-160mg/d respectively,the doses regulation period was 2 weeks. After blindopen, irbsartan group continued to the sib week.ABPM were measured in another 21 patients before and after treatment with irbsartan 150mg.d-1 for 4 weeks, and T/ P ratio was calculated. RESULTS: The blood pressure of patients decreased significantly after 2 or 4 weeks treatment .The total effective rates were 78.2% and 74.5% respectively, there wasnit any difference between two groups. T/P ofirbratan was 53.5%. Blood pressure decreased continously in the open-treatment period from the 4th week to the 8th week.The incidence of adverse reaction was 17. 1% and 13.9% in 2 groups respectively,which were mild and tolerable. CONCLUSION: Irbsartan and valsratan are effective and safe in treating mild to moderate essential hypertention.